Not medical advice. TB-500 is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
TB-500 (a Thymosin Beta-4–related fragment) is researched for actin -the cell’s internal scaffolding -and how cells move during repair. That makes it a frequent reference point in wound and soft-tissue injury science.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
TB-500 synthetic Thymosin Beta-4 fragment promotes systemic tissue repair via G-actin sequestration, angiogenesis, and NF-κB-mediated anti-inflammatory signaling.
Peer-reviewed literature typically discusses TB-500 in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Compounds in this family are frequently studied in models of tissue injury, wound closure, and how cells reorganise after damage. Research looks at cell movement, blood-vessel support, and inflammatory balance -not at replacing medical care.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 2-2.5 mg twice weekly (loading); 2-2.5 mg weekly (maintenance) · Twice weekly for 4-6 weeks loading phase, then weekly or biweekly maintenance · Subcutaneous t½ = 1.5-3 hours in rodent models. Cmax 200-400 ng/mL at Tmax 0.5-1 hr (6 mg/kg dose). Full-length Tβ4 MW 4921 Da (43 aa); TB-500 fragment MW 889 Da (7 aa). As an intrinsically unstructured peptide, it adopts minimal secondary structure in solution.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
TB-500 is a synthetic seven-amino-acid peptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4, a protein found naturally in most human cells. It is made by solid-phase peptide synthesis and supplied as a lyophilised research-grade powder for laboratory use only.
In preclinical research TB-500 is studied as a tissue-repair and cell-migration peptide. Published animal studies report regulation of G-actin (cytoskeletal remodelling), promotion of angiogenesis (new blood-vessel growth), endothelial and keratinocyte migration, and modulation of NF-κB-driven inflammation. These are findings in cell and animal models, not demonstrated human effects.
In the research literature TB-500 is used as a tool compound to study tendon, ligament, muscle, cardiac and wound-tissue repair, plus cell migration and angiogenesis. New-U supplies it strictly for in-vitro and animal-model research; it is not for human use and no therapeutic use is implied.
In published animal studies TB-500 has generally been well tolerated, but there are no controlled human safety trials, so human safety is not established. It is also WADA-prohibited for competing athletes. It is a research compound, not a medicine; New-U makes no human-use or safety claims and supplies it for laboratory research only.
Experimental parameters in the published literature vary widely by model, species, route, formulation and study endpoint, so there is no single standard figure. Any quantities reported in studies are experimental parameters from controlled research settings only — New-U does not provide human-use dosing, administration, cycle, or protocol guidance, and TB-500 is supplied strictly for laboratory research.
Thymosin Beta-4 is the full 43-amino-acid protein found naturally in most human cells. TB-500 is a synthetic seven-amino-acid fragment (Ac-LKKTETQ) that preserves the actin-binding domain responsible for most of the parent protein's wound-healing activity. The shorter peptide is much cheaper to synthesise and is widely used as a research surrogate.
Both are research peptides in the healing category but they act through different mechanisms. BPC-157 primarily drives VEGFR2/eNOS and FAK signalling, while TB-500 works through actin regulation and NF-κB modulation. Many preclinical protocols combine them to exploit the distinct pathways.
No. TB-500 is an investigational research peptide and is not approved for human therapeutic use by any major regulator. It is also on the World Anti-Doping Agency (WADA) prohibited list for competing athletes. Material is supplied strictly for laboratory research.
Store the lyophilised powder frozen and protected from light. Once placed into solution under laboratory conditions, keep it cold (1–6 °C) and protected from light, and follow the batch-specific handling documentation. Peptide material degrades slowly under cold, dark storage.
New-U supplies TB-500 in 10-vial research packs at 5 mg and 10 mg per vial, with the larger vials lowering the per-mg cost. For laboratory preparation, lyophilised TB-500 is dissolved in bacteriostatic water: concentration in mg/mL equals the vial mass in mg divided by the millilitres of diluent added (e.g. a 5 mg vial in 2.5 mL gives 2 mg/mL). All material is research-use-only; no human-use dosing instructions are provided.
The TB-500 fragment (Ac-LKKTETQ, formula C₃₇H₆₆N₁₀O₁₄) has a molecular weight of 889.02 Da, far smaller than the 4921 Da full-length 43-amino-acid Thymosin Beta-4 it derives from. Rodent pharmacokinetics report a subcutaneous elimination half-life of roughly 1.5-3 hours, with peak plasma concentration (Cmax 200-400 ng/mL) reached 0.5-1 hour after dosing.
TB-500 and BPC-157 are studied together because they support tissue repair through different mechanisms: TB-500 through G-actin regulation, angiogenesis, and NF-κB modulation, and BPC-157 through the VEGFR2/eNOS pathway and growth-hormone-receptor upregulation. New-U Research Compounds supplies both as separate research-grade vials for laboratories investigating the combination. This is a research observation, not a human-use protocol.
Yes. TB-500 (and Thymosin Beta-4-related peptides) are on the World Anti-Doping Agency (WADA) prohibited list at all times. New-U supplies TB-500 strictly for in-vitro and preclinical laboratory research, not for human use, veterinary use, or athletic performance enhancement.
It depends on the peptide. TB-500 (a Thymosin Beta-4 fragment) has a relatively short residence time, so once administration stops in a study the compound clears and no longer engages actin-binding and cell-migration pathways — observed tissue-repair processes lose ongoing stimulus rather than reversing abruptly. Unlike hormone-axis peptides, the research literature does not describe a suppression-rebound on cessation. These are preclinical research observations; TB-500 is supplied for laboratory research only and is not for human use.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside TB-500.
Primary literature and registries for TB-500, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: Thymosin Beta-4 Fragment, Tβ4, TB4, TB-500, Fequesetide, Ac-LKKTETQ, Thymosin β4 Active Fragment, Actin-Binding Peptide